• Pluri entered a partnership agreement with ZEO ScientifiX on October 26, 2026, to license its regenerative medicine portfolio.
• ZEO will receive exclusive US commercialization rights at closing, with potential expansion to Latin America.
• The transactions will give Pluri 50% of ZEO's outstanding shares; royalties increase as its equity ownership declines.
• Five-year warrants will allow purchases of an additional 5% stake at $4 per share and 2.5% at $5.50 per share.
• An additional 5% equity stake becomes payable when ZEO's volume-weighted average closing share price reaches $5.50 over 10 trading days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pluri Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-114079), on October 30, 2026, and is solely responsible for the information contained therein.